Annual Report

Overview

The report records 2023 revenue of RMB73.2 million amid continued commercialization of the caFFR and calMR systems, while also describing the acquisition of Tianjin Yuehekan and expansion into in vitro diagnostics. It is Rainmed's first ESG report and covers 2023 environmental and social performance, including 964.74 tonnes of greenhouse gas emissions, 1,641.05 MWh of energy consumption and zero work-related fatalities. The report also details Board-led ESG governance, materiality assessment, employee programs and product-quality controls.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language: English
Pages
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services